New Therapeutic Targets for the Treatment of Erectile Dysfunction

Journal of Sexual Medicine

Volumn 8, Issue 12, 2011, Pages 3271-3290

  Decaluwé, Kelly ^a   Pauwels, Bart ^a   Verpoest, Sara ^a   Van de Voorde, Johan ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Erectile dysfunction; Pharmacotherapy; Review

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ARGININE; AS 702224; ATORVASTATIN; ATRIAL NATRIURETIC FACTOR; BMS 193884; CALCITONIN GENE RELATED PEPTIDE; CITRULLINE; CYCLIC GMP; HISTAMINE; IRBESARTAN; ISOXSUPRINE; LINSIDOMINE; LOSARTAN; MELANOTAN II; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENTOLAMINE MESYLATE; PNU 83757; PROSTAGLANDIN E1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RO 70 0004 03; SAR 704899; SILDENAFIL; SILDENAFIL NITRATE; TADALAFIL; TETRAHYDROBIOPTERIN; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VARDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; EXTRACORPOREAL LITHOTRIPSY; GENE THERAPY; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TISSUE ENGINEERING;

EID: 82955249249     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02459.x     Document Type: Review

References (121)

1. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
2. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, Munarriz R, Lee SW. Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7(Pt 2):524-40.
3. McNamara ER, Donatucci CF. Newer phosphodiesterase inhibitors: Comparison with established agents. Urol Clin North Am 2011;38:155-63.
4. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: The day after. Eur Urol 2007;51:75-88.
5. Smith IA, McLeod N, Rashid P. Erectile dysfunction-When tablets don't work. Aust Fam Physician 2010;39:301-5.
6. Giammusso B, Colpi GM, Cormio L, Ludovico G, Soli M, Ponchietti R, Montorsi F, Panzironi C, Guastella B. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Urol Int 2008;81:409-15.
7. Gur S, Kadowitz PJ, Trost L, Hellstrom WJ. Optimizing nitric oxide production by time dependent L-arginine administration in isolated human corpus cavernosum. J Urol 2007;178(Pt 1):1543-8.
8. Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectile function. Pharmacol Ther 2005;106:233-66.
9. Klotz T, Mathers MJ, Braun M, Bloch W, Engelmann U. Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Urol Int 1999;63:220-3.
10. Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: Results of a double-blind, randomized, placebo-controlled study. BJU Int 1999;83:269-73.
11. Cormio L, De SM, Lorusso F, Selvaggio O, Mirabella L, Sanguedolce F, Carrieri G. Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology 2011;77:119-22.
12. Masuda H. Significance of nitric oxide and its modulation mechanisms by endogenous nitric oxide synthase inhibitors and arginase in the micturition disorders and erectile dysfunction. Int J Urol 2008;15:128-34.
13. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: In diabetic-associated erectile dysfunction. Biochem Biophys Res Commun 2001;283:923-7.
14. Kim NN, Cox JD, Baggio RF, Emig FA, Mistry SK, Harper SL, Speicher DW, Morris SM, Jr, Ash DE, Traish A, Christianson DW. Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry 2001;40:2678-88.
15. Johnson JM, Bivalacqua TJ, Lagoda GA, Burnett AL, Musicki B. eNOS-uncoupling in age-related erectile dysfunction. Int J Impot Res 2011;23:43-8.
16. Sommer F, Klotz T, Steinritz D, Bloch W. Evaluation of tetrahydrobiopterin (BH4) as a potential therapeutic agent to treat erectile dysfunction. Asian J Androl 2006;8:159-67.
17. Musicki B, Liu T, Lagoda GA, Strong TD, Sezen SF, Johnson JM, Burnett AL. Hypercholesterolemia-induced erectile dysfunction: Endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase. J Sex Med 2010;7:3023-32.
18. Jin L, Lagoda G, Leite R, Webb RC, Burnett AL. NADPH oxidase activation: A mechanism of hypertension-associated erectile dysfunction. J Sex Med 2008;5:544-51.
19. Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J Androl 2006;27:335-47.
20. Barassi A, Colpi GM, Piediferro G, Dogliotti G, D'Eril GV, Corsi MM. Oxidative stress and antioxidant status in patients with erectile dysfunction. J Sex Med 2009;6:2820-5.
21. Angulo J, Peiro C, Cuevas P, Gabancho S, Fernandez A, Gonzalez-Corrochano R, La Fuente JM, Baron AD, Chen KS, de Tejada IS. The novel antioxidant, AC3056 (2, 6-di-t-butyl-4-((dimethyl-4-methoxyphenylsilyl)methyloxy)phenol), reverses erectile dysfunction in diabetic rats and improves NO-mediated responses in penile tissue from diabetic men. J Sex Med 2009;6:373-87.
22. Vicari E, La VS, Condorelli R, Calogero AE. Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process. J Sex Med 2010;7:1247-53.
23. Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, Gandini L, Buchetti B, Lenti L, Jannini EA, Lenzi A. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: A double-blind, placebo-controlled study. Eur Urol 2007;52:1768-74.
24. Petrov VI, Vekel'yan AS, Martyushev AV, Sergeeva SA, Smolenov IV, Epstein OI. Impaza and sildenafil: Comparison of clinical effectiveness in patients with erectile dysfunction. Bull Exp Biol Med 2003;135(suppl 7):150-1.
25. Zhavbert ES, Kachanova MV, Tarasov SA, Dugina YL, Sergeeva SA, Dovgalevskii PY, Epshtein OI. Evaluation of the efficiency and safety of combined treatment with impaza and nitrates in CHD patients with erectile dysfunction. Bull Exp Biol Med 2009;148:325-7.
26. O'Connor DM, O'Brien T. Nitric oxide synthase gene therapy: Progress and prospects. Expert Opin Biol Ther 2009;9:867-78.
27. Bivalacqua TJ, Burnett AL, Hellstrom WJ, Champion HC. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: Influence of in vivo gene therapy of anti-arginase. Am J Physiol Heart Circ Physiol 2007;292:H1340-51.
28. Magee TR, Kovanecz I, Davila HH, Ferrini MG, Cantini L, Vernet D, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF. Antisense and short hairpin RNA (shRNA) constructs targeting PIN (Protein Inhibitor of NOS) ameliorate aging-related erectile dysfunction in the rat. J Sex Med 2007;4:633-43.
29. Deng W, Bivalacqua TJ, Champion HC, Hellstrom WJ, Murthy SN, Kadowitz PJ. Superoxide dismutase-A target for gene therapeutic approach to reduce oxidative stress in erectile dysfunction. Methods Mol Biol 2010;610:213-27.
30. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52:375-414.
31. Brioni JD, Nakane M, Hsieh GC, Moreland RB, Kolasa T, Sullivan JP. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res 2002;14:8-14.
32. Scatena R, Bottoni P, Martorana GE, Giardina B. Nitric oxide donor drugs: An update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 2005;14:835-46.
33. Wegner HE, Knispel HH, Klan R, Miller K. Efficacy of linsidomine chlorhydrate, a direct nitric oxide donor, in the treatment of human erectile dysfunction: Results of a double-blind cross over trial. Int J Impot Res 1995;7:233-7.
34. Gur S, Kadowitz PJ, Hellstrom WJ. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. Curr Pharm Des 2010;16:1619-33.
35. Albersen M, Shindel AW, Mwamukonda KB, Lue TF. The future is today: Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs 2010;15:467-80.
36. Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, Brioni JD. A-350619: A novel activator of soluble guanylyl cyclase. Life Sci 2003;72:1015-25.
37. Shamloul R. The potential role of the heme oxygenase/carbon monoxide system in male sexual dysfunctions. J Sex Med 2009;6:324-33.
38. Abdel Aziz MT, Mostafa T, Atta H, Mahfouz S, Wassef M, Fouad H, Kamel M, Rashed L, Sabry D, Mouhamed O. Effect of HO-1 cDNA-liposome complex transfer on erectile signalling of aged rats. Andrologia 2009;41:176-83.
39. Abdel Aziz MT, El Asmer MF, Mostafa T, Atta H, Mahfouz S, Fouad H, Rashed L, Sabry D, Hassouna A, Abdel Aziz AT, Senbel A, Demery A. Effects of losartan, HO-1 inducers or HO-1 inhibitors on erectile signaling in diabetic rats. J Sex Med 2009;6:3254-64.
40. Sousa CM, Havt A, Santos CF, Arnaud-Batista FJ, Cunha KM, Cerqueira JB, Fonteles MC, Nascimento NR. The relaxation induced by uroguanylin and the expression of natriuretic peptide receptors in human corpora cavernosa. J Sex Med 2010;7:3610-9.
41. Christ GJ. Membrane bound guanylyl cyclase as a potential molecular target for the treatment of erectile dysfunction. J Urol 2003;169:1918-22.
42. Yang R, Wang J, Chen Y, Sun Z, Wang R, Dai Y. Effect of caffeine on erectile function via up-regulating cavernous cyclic guanosine monophosphate in diabetic rats. J Androl 2008;29:586-91.
43. Mirone V, Palmieri A, Nistico G. Intracavernous cyclic GMP produces penile erection in patients with erectile dysfunction. Br J Urol 1993;71:365.
44. Bivalacqua TJ, Kendirci M, Champion HC, Hellstrom WJ, Andersson KE, Hedlund P. Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: Influence of in vivo gene therapy of PKG1alpha. BJU Int 2007;99:1488-94.
45. Spektor M, Rodriguez R, Rosenbaum RS, Wang HZ, Melman A, Christ GJ. Potassium channels and human corporeal smooth muscle cell tone: Further evidence of the physiological relevance of the Maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro. J Urol 2002;167:2628-35.
46. Kun A, Matchkov VV, Stankevicius E, Nardi A, Hughes AD, Kirkeby HJ, Demnitz J, Simonsen U. NS11021, a novel opener of large-conductance Ca(2+)-activated K(+) channels, enhances erectile responses in rats. Br J Pharmacol 2009;158:1465-76.
47. Venkateswarlu K, Giraldi A, Zhao W, Wang HZ, Melman A, Spektor M, Christ GJ. Potassium channels and human corporeal smooth muscle cell tone: Diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers. J Urol 2002;168:355-61.
48. Vick RN, Benevides M, Patel M, Parivar K, Linnet O, Carson CC. The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. J Urol 2002;167:2618-23.
49. Christ GJ, Andersson KE, Williams K, Zhao W, D'Agostino R, Jr, Kaplan J, Aboushwareb T, Yoo J, Calenda G, Davies KP, Sellers RS, Melman A. Smooth-muscle-specific gene transfer with the human maxi-k channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol 2009;56:1055-66.
50. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. hMaxi-K gene transfer in males with erectile dysfunction: Results of the first human trial. Hum Gene Ther 2006;17:1165-76.
51. So I, Chae MR, Lee SW. Gene transfer of the K(ATP) channel restores age-related erectile dysfunction in rats. BJU Int 2007;100:1154-60.
52. Nimmegeers S, Decaluwé K, Van de Voorde J. Characterization of the effect of histamine on mouse corpus cavernosum. Inflamm Res 2008;57(suppl 1):S59-60.
53. Cara AM, Lopes-Martins RA, Antunes E, Nahoum CR, De NG. The role of histamine in human penile erection. Br J Urol 1995;75:220-4.
54. Gozes I, Reshef A, Salah D, Rubinraut S, Fridkin M. Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment. Endocrinology 1994;134:2121-5.
55. Shen ZJ, Wang H, Lu YL, Zhou XL, Chen SW, Chen ZD. Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. BJU Int 2005;95:890-4.
56. Roy JB, Petrone RL, Said SI. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection. J Urol 1990;143:302-4.
57. Sandhu D, Curless E, Dean J, Hackett G, Liu S, Savage D, Oakes R, Frentz G. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res 1999;11:91-7.
58. Stief CG, Benard F, Bosch RJ, Aboseif SR, Lue TF, Tanagho EA. A possible role for calcitonin-gene-related peptide in the regulation of the smooth muscle tone of the bladder and penis. J Urol 1990;143:392-7.
59. Bivalacqua TJ, Champion HC, Abdel-Mageed AB, Kadowitz PJ, Hellstrom WJ. Gene transfer of prepro-calcitonin gene-related peptide restores erectile function in the aged rat. Biol Reprod 2001;65:1371-7.
60. Xing JP, Cui XF, Sun JH, Qiu SD. Effect of secretory human calcitonin gene-related peptide recombinant AAV on penile erection in streptozotocin-induced diabetic rat. Zhonghua Nan Ke Xue 2005;11:775-9.
61. Stief CG, Wetterauer U, Schaebsdau FH, Jonas U. Calcitonin-gene-related peptide: A possible role in human penile erection and its therapeutic application in impotent patients. J Urol 1991;146:1010-4.
62. Truss MC, Becker AJ, Thon WF, Kuczyk M, Djamilian MH, Stief CG, Jonas U. Intracavernous calcitonin gene-related peptide plus prostaglandin E1: Possible alternative to penile implants in selected patients. Eur Urol 1994;26:40-5.
63. He L, Wen J, Jiang X, Chen H, Tang Y. Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China. Andrologia 2011;43:208-12.
64. Brugger N, Kim NN, Araldi GL, Traish AM, Palmer SS. Pharmacological and functional characterization of novel EP and DP receptor agonists: DP1 receptor mediates penile erection in multiple species. J Sex Med 2008;5:344-56.
65. Angulo J, Cuevas P, Fernandez A, Allona A, Moncada I, Martin-Morales A, La Fuente JM, de Tejada IS. Enhanced thromboxane receptor-mediated responses and impaired endothelium-dependent relaxation in human corpus cavernosum from diabetic impotent men: Role of protein kinase C activity. J Pharmacol Exp Ther 2006;319:783-9.
66. Gur S, Kadowitz PJ, Rho HWJ. A/Rho-Kinase as a therapeutic target for the male urogenital tract. J Sex Med 2011;8:675-87.
67. Jin L, Rho BAL. A/Rho-kinase in erectile tissue: Mechanisms of disease and therapeutic insights. Clin Sci (Lond) 2006;110:153-65.
68. Jin L, Liu T, Lagoda GA, Champion HC, Bivalacqua TJ, Elevated BAL. RhoA/Rho-kinase activity in the aged rat penis: Mechanism for age-associated erectile dysfunction. FASEB J 2006;20:536-8.
69. Lohn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, Schaefer M, Linz W, Kohlmann M, Herbert JM, Janiak P, O'Connor SE, Ruetten H. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 2009;54:676-83.
70. Linder AE, Webb RC, Mills TM, Ying Z, Lewis RW, Teixeira CE. Rho-kinase and RGS-containing RhoGEFs as molecular targets for the treatment of erectile dysfunction. Curr Pharm Des 2005;11:4029-40.
71. Wingard CJ, Moukdar F, Prasad RY, Cathey BL, Wilkinson L. Reversal of voltage-dependent erectile responses in the Zucker obese-diabetic rat by rosuvastatin-altered RhoA/Rho-kinase signaling. J Sex Med 2009;6(suppl 3):269-78.
72. Morelli A, Chavalmane AK, Filippi S, Fibbi B, Silvestrini E, Sarchielli E, Zhang XH, Vignozzi L, Vannelli GB, Forti G, Maggi M. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med 2009;6:91-106.
73. Fibbi B, Morelli A, Marini M, Zhang XH, Mancina R, Vignozzi L, Filippi S, Chavalmane A, Silvestrini E, Colli E, Adorini L, Vannelli GB, Maggi M. Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway. J Androl 2008;29:70-84.
74. Herrmann HC, Levine LA, Macaluso J, Jr, Walsh M, Bradbury D, Schwartz S, Mohler ER, III, Kimmel SE. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 2006;3:303-8.
75. Hong SK, Han BK, Jeong SJ, Byun SS, Lee SE. Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy. J Urol 2007;178:613-6.
76. Andersson KE, Stief C. Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction. World J Urol 2001;19:9-13.
77. Goldstein I, Carson C, Rosen R, Islam A. Vasomax for the treatment of male erectile dysfunction. World J Urol 2001;19:51-6.
78. Enzlin P, Vanderschueren D, Bonte L, Vanderborght W, Declercq G, Demyttenaere K. Trazodone: A double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings. Int J Impot Res 2000;12:223-8.
79. Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: A systematic review and meta-analysis. BJU Int 2003;92:441-6.
80. Choppin A, Blue DR, Hegde SS, Gennevois D, McKinnon SA, Mokatrin A, Bivalacqua TJ, Hellstrom WJ. Evaluation of oral ro70-0004/003, an alpha1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction. Int J Impot Res 2001;13:157-61.
81. Gur S, Kadowitz PJ, Hellstrom WJ. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction: Implications for sexual dysfunction. Drugs 2008;68:209-29.
82. Cirino G, Sorrentino R, di Villa BR, Popolo A, Palmieri A, Imbimbo C, Fusco F, Longo N, Tajana G, Ignarro LJ, Mirone V. Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Proc Natl Acad Sci U S A 2003;100:5531-6.
83. Jin LM. Angiotensin II signaling and its implication in erectile dysfunction. J Sex Med 2009;6(suppl 3):302-10.
84. Schlimmer N, Kratz M, Bohm M, Baumhakel M. Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis. Br J Pharmacol 2011;163:804-14.
85. Speel TG, Kiemeney LA, Thien T, Smits P, Meuleman EJ. Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: A pilot study. J Sex Med 2005;2:207-12.
86. Baumhakel M, Schlimmer N, Bohm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008;20:493-500.
87. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003;2:29-34.
88. Llisterri JL, Lozano Vidal JV, Aznar VJ, Argaya RM, Pol BC, Sanchez Zamorano MA, Ferrario CM. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001;321:336-41.
89. Yousif MH, Kehinde EO, Benter IF. Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum. Pharmacol Res 2007;56:209-16.
90. da Costa Goncalves AC, Leite R, Fraga-Silva RA, Pinheiro SV, Reis AB, Reis FM, Touyz RM, Webb RC, Alenina N, Bader M, Santos RA. Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function. Am J Physiol Heart Circ Physiol 2007;293:H2588-96.
91. Chu LL, Adaikan PG. Role of chloride channels in the regulation of corpus cavernosum tone: A potential therapeutic target for erectile dysfunction. J Sex Med 2008;5:813-21.
92. Khan MA, Calvert RC, Sullivan ME, Thompson CS, Mumtaz FH, Morgan RJ, Mikhailidis DP. Normal and pathological erectile function: The potential clinical role of endothelin-1 antagonists. Curr Drug Targets 2000;1:247-60.
93. Kim NN, Dhir V, Azadzoi KM, Traish AM, Flaherty E, Goldstein I. Pilot study of the endothelin-A receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction. J Androl 2002;23:76-83.
94. Ritchie R, Sullivan M. Endothelins & erectile dysfunction. Pharmacol Res 2011;63:496-501.
95. Ghasemi M, Sadeghipour H, Dehpour AR. Anandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: Involvement of cannabinoid CB1 and vanilloid VR1 receptors. BJU Int 2007;100:1385-90.
96. Castelli MP, Piras AP, Melis T, Succu S, Sanna F, Melis MR, Collu S, Ennas MG, Diaz G, Mackie K, Argiolas A. Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: Immunocytochemistry, autoradiography and behavioral studies. Neuroscience 2007;147:197-206.
97. Pointis G. Connexin43: Emerging role in erectile function. Int J Biochem Cell Biol 2006;38:1642-6.
98. Lysiak JJ, Kavoussi PK, Ellati RT, Steers WD, Annex BH. Angiogenesis therapy for the treatment of erectile dysfunction. J Sex Med 2010;7:2554-63.
99. Tomada N, Tomada I, Vendeira P, Neves D. Expression of vascular endothelial growth factor and angiopoietins in human corpus cavernosum. BJU Int 2010;105:269-73.
100. Jin HR, Kim WJ, Song JS, Piao S, Tumurbaatar M, Shin SH, Choi MJ, Tuvshintur B, Song KM, Kwon MH, Yin GN, Koh GY, Ryu JK, Suh JK. Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse. J Sex Med 2010;7:3635-46.
101. Pu XY, Wang XH, Gao WC, Yang ZH, Li SL, Wang HP, Wu YL. Insulin-like growth factor-1 restores erectile function in aged rats: Modulation the integrity of smooth muscle and nitric oxide-cyclic guanosine monophosphate signaling activity. J Sex Med 2008;5:1345-54.
102. Bakircioglu ME, Lin CS, Fan P, Sievert KD, Kan YW, Lue TF. The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence. J Urol 2001;165(Pt 1):2103-9.
103. Bella AJ, Lin G, Lin CS, Hickling DR, Morash C, Lue TF. Nerve growth factor modulation of the cavernous nerve response to injury. J Sex Med 2009;6(suppl 3):347-52.
104. Sezen SF, Lagoda G, Burnett AL. Role of immunophilins in recovery of erectile function after cavernous nerve injury. J Sex Med 2009;6(suppl 3):340-6.
105. King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem 2007;7:1098-106.
106. Krishna R, Wong P, Stevens C, De LI, Van DK, Rosen RC, Gendrano IN, III, Peeters M, Wagner JA, Herman GA. Lack of erectogenic activity of a novel selective melanocortin-4 receptor agonist in a clinical experimental model. J Clin Pharmacol 2008;48:1237-41.
107. Lansdell MI, Hepworth D, Calabrese A, Brown AD, Blagg J, Burring DJ, Wilson P, Fradet D, Brown TB, Quinton F, Mistry N, Tang K, Mount N, Stacey P, Edmunds N, Adams C, Gaboardi S, Neal-Morgan S, Wayman C, Cole S, Phipps J, Lewis M, Verrier H, Gillon V, Feeder N, Heatherington A, Sultana S, Haughie S, Martin SW, Sudworth M, Tweedy S. Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans. J Med Chem 2010;53:3183-97.
108. Miner MM, Seftel AD. Centrally acting mechanisms for the treatment of male sexual dysfunction. Urol Clin North Am 2007;34:483-96.
109. Melis MR, Argiolas A. Central control of penile erection: A re-visitation of the role of oxytocin and its interaction with dopamine and glutamic acid in male rats. Neurosci Biobehav Rev 2011;35:939-55.
110. Nickel M, Moleda D, Loew T, Rother W, Pedrosa GF. Cabergoline treatment in men with psychogenic erectile dysfunction: A randomized, double-blind, placebo-controlled study. Int J Impot Res 2007;19:104-7.
111. d'Emmanuele de Villa Bianca R, Sorrentino R, Roviezzo F, Imbimbo C, Palmieri A, De Dominicis G, Montorsi F, Cirino G, Mirone V. Peripheral relaxant activity of apomorphine and of a D1 selective receptor agonist on human corpus cavernosum strips. Int J Impot Res 2005;17:127-33.
112. Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ, III, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem 2004;47:3853-64.
113. Enguehard-Gueiffier C, Gueiffier A. Recent progress in medicinal chemistry of D4 agonists. Curr Med Chem 2006;13:2981-93.
114. Argiolas A, Melis MR. Central control of penile erection: Role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol 2005;76:1-21.
115. Yonezawa A, Yoshizumi M, Ebiko M, Ise SN, Watanabe C, Mizoguchi H, Kimura Y, Sakurada S. Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: Differential roles of 5-HT2 receptor subtypes. Pharmacol Biochem Behav 2008;88:367-73.
116. Kimura Y, Naitou Y, Wanibuchi F, Yamaguchi T. Characterization of intracavernous pressure increase induced by Ym348, a novel 5-HT2C receptor agonist, in anesthetized rats. J Urol 2006;175:1953-7.
117. Melis MR, Succu S, Mascia MS, Cortis L, Argiolas A. Extracellular excitatory amino acids increase in the paraventricular nucleus of male rats during sexual activity: Main role of N-methyl-d-aspartic acid receptors in erectile function. Eur J Neurosci 2004;19:2569-75.
118. Andersson KE, Hedlund P. New directions for erectile dysfunction therapies. Int J Impot Res 2002;14(suppl 1):S82-92.
119. Harraz A, Shindel AW, Lue TF. Emerging gene and stem cell therapies for the treatment of erectile dysfunction. Nat Rev Urol 2010;7:143-52.
120. Shokeir AA, Harraz AM, El-Din AB. Tissue engineering and stem cells: Basic principles and applications in urology. Int J Urol 2010;17:964-73.
121. Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol 2010;58:243-8.